Tislelizumab with chemotherapy before surgery for oral cancer
Treatments studied
Part of Cancer clinical trials.
This trial studies giving tislelizumab (an immune treatment) plus chemotherapy before surgery to shrink and treat locally advanced oral squamous cell cancer. It aims to improve tumor response and outcomes, while checking safety.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You agree to sign the informed consent form
- You have confirmed oral squamous cell carcinoma (oral cancer type)
- You’re age 18–75 and can do daily activities fairly well (ECOG performance status 0–1)
- Your cancer is locally advanced stage III or IVb, and your doctor can measure at least one visible spot (measurable lesion)
- You have not had prior full-course cancer treatments for this oral cancer (no prior chemo, immune checkpoint drugs like anti–PD-1/PD-L1, or similar targeted immune drugs)
- Your blood, liver, kidney, clotting, and heart test results are within required limits, and you can use effective birth control
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether giving chemotherapy plus immunotherapy before surgery can help treat advanced mouth cancer. It aims to shrink tumors and improve outcomes.
This trial tests giving anti–PD-1 immunotherapy plus a drug called TP before surgery for oral squamous cell carcinoma (mouth/throat cancer). The goal is to see whether this pre-surgery treatment improves how much the tumor responds under the microscope.
This Phase 2 trial tests giving the immunotherapy drug sintilimab before surgery, along with fewer chemotherapy cycles. The goal is to shrink or control oral or throat squamous cell cancers while keeping side effects lower, before the tumor is removed.
This trial tests a combination of immunotherapy (tirilizumab) and two chemotherapy drugs (albumin-bound paclitaxel and cisplatin) for people with advanced but removable oral cancer. The goal is to see if this treatment shrinks the tumor before surgery and improves outcomes.
This trial is testing a new combination of an immunotherapy drug (adebrelimab) plus two chemotherapy drugs (paclitaxel and carboplatin) given before surgery for advanced oral cancer. The goal is to see if this treatment can shrink the tumor and improve outcomes.
This trial tests a combination of drugs (tislelizumab, cetuximab, and chemotherapy) given before surgery to treat mouth or throat cancer that has come back. The goal is to shrink the tumor and improve surgery outcomes.
Hear when a new Oral Squamous Cell Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.